Home/Filings/4/0001193125-25-317962
4//SEC Filing

Wallace Eli M. 4

Accession 0001193125-25-317962

CIK 0001869105other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 7:04 PM ET

Size

6.0 KB

Accession

0001193125-25-317962

Insider Transaction Report

Form 4
Period: 2025-12-10
Wallace Eli M.
DirectorChief Executive Officer
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-12-101,114,400500,000 total
    Exercise: $12.44Exp: 2035-10-01Common Stock (1,114,400 underlying)
Footnotes (2)
  • [F1]1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
  • [F2]On December 10, 2025, the Issuer rescinded 1,114,400 stock options that were part of the Reporting Person's option grant dated October 2, 2025 (the "Rescinded Portion"). The Rescinded Portion was cancelled and the remaining 500,000 stock options from the original grant continue to remain outstanding. The rescission was an exempt disposition to the Issuer per Rule 16b-3.

Documents

1 file

Issuer

BridgeBio Oncology Therapeutics, Inc.

CIK 0001869105

Entity typeother

Related Parties

1
  • filerCIK 0001776352

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 7:04 PM ET
Size
6.0 KB